| WB | 1/1000-1/5000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CDC25A2 |
| WB Predicted band size | 59 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human CDC25A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDC25A抗体的参考文献示例(内容为虚构，仅作格式参考)：
1. **"CDC25A phosphatase as a biomarker in colorectal cancer: Antibody-based detection and clinical implications"**
*Authors: J. Smith et al.*
摘要：本研究利用特异性CDC25A抗体，通过免疫组化分析结直肠癌组织，发现CDC25A高表达与患者生存率降低显著相关，提示其作为预后标志物的潜力。
2. **"Development of a monoclonal antibody targeting CDC25A for cell cycle regulation studies"**
*Authors: L. Chen & M. Tanaka*
摘要：报道了一种新型抗CDC25A单克隆抗体的开发，验证其在Western blot和免疫荧光中的特异性，并用于探究CDC25A在G1/S期检查点中的功能调控。
3. **"Ubiquitin-mediated degradation of CDC25A: Insights from siRNA and antibody inhibition experiments"**
*Authors: R. Gupta et al.*
摘要：结合RNA干扰和CDC25A抗体阻断实验，揭示了泛素-蛋白酶体系统对CDC25A的降解机制，阐明其在DNA损伤应答中的动态调控。
4. **"CDC25A overexpression in triple-negative breast cancer: Therapeutic target validation via neutralizing antibodies"**
*Authors: E. Martínez et al.*
摘要：通过中和性CDC25A抗体抑制乳腺癌细胞增殖，证实靶向CDC25A可增强化疗敏感性，为三阴性乳腺癌治疗提供新策略。
(注：以上文献及作者为模拟示例，实际引用请查询PubMed等数据库获取真实研究。)
CDC25A is a dual-specificity phosphatase belonging to the CDC25 family, which plays a critical role in regulating cell cycle progression. It primarily activates cyclin-dependent kinases (CDKs) by removing inhibitory phosphorylations, thereby driving transitions through the G1/S and G2/M checkpoints. Overexpression or dysregulation of CDC25A is linked to uncontrolled cell proliferation, genomic instability, and tumorigenesis, making it a biomarker of interest in cancers such as breast, lung, and colorectal malignancies.
Antibodies targeting CDC25A are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to quantify protein levels or assess subcellular distribution. High-quality CDC25A antibodies are typically validated for specificity using knockout (KO) cell lines or siRNA-mediated knockdown to minimize cross-reactivity with homologous family members (e.g., CDC25B/C). Species reactivity often includes human, mouse, and rat samples.
In cancer research, CDC25A antibodies help evaluate its prognostic significance and therapeutic potential. Small-molecule inhibitors targeting CDC25A are under investigation, and these antibodies aid in mechanistic studies of drug efficacy. Challenges include distinguishing post-translational modifications (e.g., phosphorylation) that regulate CDC25A stability during DNA damage responses. Researchers must optimize experimental conditions to account for such dynamic changes, ensuring accurate interpretation of CDC25A-related pathways in health and disease.
×
